Irish company Aerogen, a medical device and drug delivery company has been awarded the internationally prestigious Ruban d'Honneur award in the European Business Awards. The award is in recognition of Aerogen's global growth strategy, which has seen the business grow by 30% year on year. This is the first Irish medical devices company to receive the Ruban d'Honneur.
Aerogen is an innovative medical device and drug delivery company specialising in the design, manufacture and marketing of aerosol drug delivery systems, aimed predominately at the critical care respiratory market. Aerogen employs 40 people from its Irish facility, and its high end nebuliser products are today used in acute care facilities in 65 countries throughout the world.
Alan Duffy, Head of HSBC Corporate Banking Ireland, who's parent company sponsor the awards commented; "I'm absolutely delighted Aerogen have been recognised with a Ruban d'Honneur. The medical devices sector is an area where Ireland is showing real strength and growth at the moment and Aerogen are certainly at the forefront of this."
The European Business Awards is dedicated to raising the visibility and progress of companies who excel in delivering innovation twinned with successful commercial results. Last year the European Business Awards showcased 100 Ruban d'Honneur recipients with a combined turnover greater than €766 billion Euros (6% of EU GDP) who employ over 3.5 million people.
John Power, CEO of Aerogen said "At a time when the focus for economic recovery is on promoting export led growth, we're delighted to receive a Ruban d'Honneur accolade. Aerogen has worked hard to establish a focused growth strategy which has enabled us to expand our business into new market areas such as drug delivery partnerships, alongside our core product offerings. In fact, since our management buyout in 2008 we have quadrupled sales."
Aerogen's international growth strategy has helped the company to create and sustain a competitive advantage in the drug delivery and medical device sector. Aerogen created an uncontested market place by delivering the first vibrating mesh technology to the Intensive Care hospital setting. Growing this core quotient of users has been key to Aerogen's progress. Through a structured diffusion strategy Aerogen's technology is used in a variety of settings, from critical hospital settings to home care, as well as enabling the technology to be used in drug delivery combinations.
Research shows disparity in pediatric hospital access between rural and urban areas